- Home
- PETS vs ASMB Comparison
PETS vs ASMB Comparison
Compare PETS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ASMB
- Stock Information
- Founded
- PETS 1996
- ASMB 2005
- Country
- PETS United States
- ASMB United States
- Employees
- PETS N/A
- ASMB N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ASMB Health Care
- Exchange
- PETS Nasdaq
- ASMB Nasdaq
- Market Cap
- PETS 82.0M
- ASMB 110.8M
- IPO Year
- PETS N/A
- ASMB 2010
- Fundamental
- Price
- PETS $3.98
- ASMB $16.79
- Analyst Decision
- PETS Sell
- ASMB Buy
- Analyst Count
- PETS 2
- ASMB 2
- Target Price
- PETS $3.50
- ASMB $35.00
- AVG Volume (30 Days)
- PETS 174.8K
- ASMB 28.7K
- Earning Date
- PETS 10-28-2024
- ASMB 11-06-2024
- Dividend Yield
- PETS 28.95%
- ASMB N/A
- EPS Growth
- PETS N/A
- ASMB N/A
- EPS
- PETS N/A
- ASMB N/A
- Revenue
- PETS $270,772,000.00
- ASMB $21,481,000.00
- Revenue This Year
- PETS N/A
- ASMB $267.67
- Revenue Next Year
- PETS $3.27
- ASMB $46.15
- P/E Ratio
- PETS N/A
- ASMB N/A
- Revenue Growth
- PETS 2.26
- ASMB N/A
- 52 Week Low
- PETS $2.90
- ASMB $7.68
- 52 Week High
- PETS $10.53
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- ASMB 51.49
- Support Level
- PETS $3.89
- ASMB $17.27
- Resistance Level
- PETS $4.22
- ASMB $18.98
- Average True Range (ATR)
- PETS 0.20
- ASMB 1.23
- MACD
- PETS -0.02
- ASMB 0.12
- Stochastic Oscillator
- PETS 47.37
- ASMB 55.03
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.